...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Research in Medical Sciences >Prevalence of virological failure amongst WHO- defined immunological failure HIV patients on first line of highly active antiretroviral therapy in a tertiary care hospital in Haryana, India
【24h】

Prevalence of virological failure amongst WHO- defined immunological failure HIV patients on first line of highly active antiretroviral therapy in a tertiary care hospital in Haryana, India

机译：印度哈里亚纳邦一家三级医院的一线高抗逆转录病毒疗法中，世卫组织定义的免疫学失败的艾滋病毒患者中病毒学失败的发生率

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: In resource limited settings in India, monitoring of treatment in HIV patients taking highly active antiretroviral therapy is done by six monthly CD4 count instead of highly sensitive plasma viral load. Patients are subjected to viral load only when their CD4 count is low for the last 12 months. This protocol has a huge disadvantage as treatment failure is detected much later than it has actually occurred and switch over to second line therapy gets delayed by approximately one year. Methods: Plasma viral load (pVL) of 50 WHO defined immunological failure cases was done using RT-PCR to detect virological failure (VF). Results: Out of 50 WHO defined immunological failure cases, 16 percent had developed virological failure. Conclusions: Nearly one-sixth of WHO defined immunological failure (IF) cases had developed virological failure. These patients required second line highly active antiretroviral therapy (HAART) therapy but due to following of current treatment monitoring protocol, treatment got delayed by one year. Thus, amendment in national policy for monitoring ART is required to diagnose treatment failure early so that there is no delay in switching to second line ART and morbidity and mortality in these patients can be reduced.
机译：背景：在印度资源有限的环境中，通过六个月的CD4计数而不是高度敏感的血浆病毒载量来监测接受高活性抗逆转录病毒疗法的HIV患者的治疗情况。仅当过去12个月的CD4计数低时，患者才接受病毒负荷。该协议具有很大的缺点，因为检测到的治疗失败要比实际发生的发生晚得多，并且切换到二线治疗的时间延迟了大约一年。方法：采用RT-PCR检测了50例WHO定义的免疫学失败病例的血浆病毒载量（pVL），以检测病毒学失败（VF）。结果：在50例WHO定义的免疫学失败病例中，有16％发生了病毒学失败。结论：世卫组织确定的免疫学失败（IF）病例中近六分之一发生了病毒学失败。这些患者需要二线高效抗逆转录病毒疗法（HAART）治疗，但由于遵循当前的治疗监测方案，治疗被推迟了一年。因此，需要对监测ART的国家政策进行修改以及早诊断治疗失败，以便不延迟转用二线ART治疗，并且可以降低这些患者的发病率和死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号